Why Fulcrum Therapeutics, Inc.’s (FULC) Stock Is Down 5.11%
As of Friday, July 31, Fulcrum Therapeutics, Inc.’s FULC share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Fulcrum Therapeutics, Inc.’s (FULC) Stock Is Down 5.69%
As of Monday, June 08, Fulcrum Therapeutics, Inc.’s FULC share price has dipped by 5.69%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Fulcrum Therapeutics, Inc.’s (FULC) Stock Is Down 52.10%
As of Tuesday, June 02, Fulcrum Therapeutics, Inc.’s FULC share price has dipped by 52.10%, which has investors questioning if this is right time to buy.Michael Rose
Why Fulcrum Therapeutics, Inc.’s (FULC) Stock Is Down 51.95%
As of Tuesday, June 02, Fulcrum Therapeutics, Inc.’s FULC share price has dipped by 51.95%, which has investors questioning if this is right time to buy.Tudor Pop
Why Fulcrum Therapeutics, Inc.’s (FULC) Stock Is Up 5.92%
As of Wednesday, May 20, Fulcrum Therapeutics, Inc.’s FULC share price has surged by 5.92%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | FULC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $286.1 | $511.9 | 31% |
|
| Shares Out (Mil) | 76.3 | 42.8 | 57% |
|
| Institutional Ownership | 98.9% | 82.8% | 83% |
|
| Float (Mil) | 63.5 | 44.4 | 52% |
|
| Beta | 2.58 | 0.70 | 96% |
|
| Avg Daily Volume (000s) | 1,543 | 372 | 77% |
|
| Price Change (52-week) |
(61.0%) | 59.4% | 15% |
|
| Growth | FULC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (1.1%) | (2.0%) | 39% |
|
| EPS (5yr) | 15.8% | 15.0% | 59 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 27.8% | (15.1%) | 85% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 3 | 6 | |
| Current EPS | ($0.107) | ($0.656) | ($0.548) | |
| Month Ago EPS | ($0.111) | ($0.657) | ($0.488) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.153) | ($0.761) | ($0.581) | |
| Year/Year Chg | (68.8%) | (44.5%) | (47.6%) | |
| Financials | FULC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($85) | ($11) | 12% |
|
| EPS (TTM) | ($1.210) | ($0.700) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($66) | ($7) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $5 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $6 | 21% |
|
| Enterprise Value (Q1) (Mil) | ($20) | $494 | 1% |
|
| Valuation | FULC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.92 | 2.24 | 21% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | FULC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (30.8%) | (22.2%) | 16% |
|
| ROE | (32.4%) | (21.4%) | 19% |
|
| Liabilities to Assets | 4.1% | 32.8% | 2% |
|
| F-Score | 3 | 3 | 18% |
|
Fulcrum Therapeutics, Inc. did not pass any screens on 10/12/2026.
